BioAro

test catalog

Focused Panels

CardiAro

OncoAro

NutriAro

PainAro

MicroAro

AgeAro

PharmAro

BeautyAro

cardiAro

BioAro’s cardiovascular panels, CardioAro Cardiomyopathy, CardioAro Hypercholesterolemia and CardioAro Amyloidosis, are aimed at exploring mutations within genes associated with cardiovascular disease.

Some of the genes explored in the panels include:

MYH7 encodes type II myosin, responsible for generation of the mechanical force that allows cardiac contraction. In the case of gene mutation, the heart’s normal contraction ability is affected. Conditions associated to such genetic changes include: Familial hypertrophic/dilated/restrictive cardiomyopathies, left ventricular noncompaction and  myosin storage myopathy, among others.

PCSK9 encodes blood cholesterol regulating proteins known as low-density lipoprotein receptors. Mutations in this gene may inhibit their ability to remove excess cholesterol from the blood, resulting in hypercholesterolemia or hypobetalipoproteinemia. 

PLN is involved in the inhibition of ATP2A2 activity in cardiac sarcoplasmic reticulum, modulating heart contractility as well as regulating its calcium homeostasis. Deletion of arginine 14 in PLN is described with early onset cardiomyopathy and accompanying lethal arrhythmias (Haghighi et al., 2006).

TTR encodes the transthyretin protein, transporting vitamin A and thyroxine throughout the body. Mutations in this gene can present as amyloidosis.

OncoAro

BioAro’s cancer panel, OncoAro is aimed at exploring mutations within genes associated with tumour formation and progression. Certain mutations can increase the likelihood of a person to develop a certain type of cancer. 

Some of the genes explored in the panel include:

AKT1 is an oncogene encoding AKT1 kinase, playing a critical role in signaling pathways related to cell proliferation, differentiation, and apoptosis. Mutations in this gene may lead to formation of cancerous cells.

CDK4 encodes key proteins (kinases), controlling cell cycle progression. Mutations in this gene may lead to uncontrolled cell division and tumorigenesis. 

EGFR provides instructions for the making of epidermal growth factor receptor. This receptor forms a complex with ligands to promote cell proliferation and survival via signaling pathways. Health conditions related to EGFR mutations are lung cancer and carcinomas.

KRAS is associated with the RAS/MAPK signaling pathway as an oncogene. Mutations in this gene is associated with several cancers.

PTEN encodes the PTEN enzyme, which is important in apoptosis induction of tumor cells. It is also involved in cell migration, adhesion and angiogenesis. When not of proper function, uncontrolled cell proliferation and tumorigenesis is often a result. Osteosarcoma, breast, bladder and lung cancer are some of the cancers associated with such mutations.

NutriAro

BioAro’s nutrigenomic panel, NutriAro is aimed at exploring mutations within genes associated with dietary component metabolism, cardio-metabolism, weight management, food intolerance, eating habits, fitness and physical activity.

Some of the genes explored in the panel include:

ACSL1 is a gene encoding protein that catalyze lipid biosynthesis and fatty acid degradation. In the case of gene mutation, an individual’s energy levels may be lower than normal.

SLC22A5 encodes sodium-ion dependent, high affinity carnitine transporters. Mutations can result in primary carnitine deficiency (often presented as muscle weakness, fatigue and hypoglycemia) and Crohn disease among other conditions.

FTO was identified as the first obesity-relatied gene. People with a certain variant of the gene have an increased risk of obesity. Multiple SNPs in the FTO gene are strongly associated with BMI, body fat rate, waist and hip circumference, and energy intake.

HLA is associated with the synthesis of Major Histocompatibility Complex (MHC), which are cell surface proteins that are responsible for the regulation of the immune system. Several SNPs have been shown to be associated with gluten intolerance and celiac disease.

More panels to be offered soon..

How Does Sequencing Work?

01

Sample Collection and DNA extraction

This step includes nucleic  acid (NA) extraction, NA  quantification, NA sample  plate preparation and  storing NA plate preparation.

02

Library preparation

Library preparation is where fragmentation, ligation and templating is done. At BioAro, this step is automized to reduce the possibility of contamination and error.
03

Sequencing

The sample is loaded onto the sequencer and after only one day, a report is generated.

04

Data Analysis and report generation

Data is analyzed for variants and are annotated. After filtration of data, the report is done.

Whole Exome Sequencing

ExomeAro

Whole Genome Sequencing

PanGeneAro

Whole Exome Sequencing

Whole Genome Sequencing

ExomeAro

PanGeneAro

Al Platforms

Al-PharmaAro

Al-Allelefind

Al-Synergy